Please login to the form below

Not currently logged in

Pfizer’s Paxlovid receives positive opinion from CHMP

Pfizer NY headquarters

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

Moderna begins phase 2 trial of Omicron-specific booster

The study will include two groups, with approximately 300 people in each group

FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments

GileadThe company confirmed that six other phase 2 trials would go ahead as previously planned

Janssen’s Tremfya receives positive results for active psoriatic arthritis

JanssenThe drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies

Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine

covidThe clinical trial involves adults aged 18 to 55 who received an Omicron-based vaccine candidate as part of a two-dose primary series, as well as a booster

FDA restricts use of certain antibody treatments for COVID-19

FDA headquarters White OakThe restrictions reflect recent data that shows these antibodies are not effective against the Omicron variant

FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies

The review of Evrysdi has been developed for pre-symptomatic babies under two months old with spinal muscular atrophy

Ipsen’s Sohonos approved by Health Canada

Ipsen buildingThe drug is the first approved treatment for individuals with fibrodysplasia ossificans progressiva

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

GileadThe FDA also issued an EUA for the treatment to include non-hospitalised paediatric patients 12 years and under who are at high risk of disease progression

Claire GillisQ&A: Claire Gillis

PME interviews VMLY&Rx's CEO

Latest appointments

COVID-19 Updates and Daily News

Featured jobs


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...